By David Sachs

 

Sandoz will buy vision-impairment drug Cimerli from Coherus BioSciences for $170 million.

The Swiss pharmaceutical company said Monday that the purchase of the U.S. company's medication includes a biologics license, product inventory, and ophthalmology sales, as well as access to proprietary commercial software.

The medication, which treats serious eye conditions including macular degeneration, is interchangeable with Lucentis, a drug developed by Genentech. Sandoz expects to close the deal in the second half of this year.

 

Write to David Sachs at david.sachs@wsj.com

 

(END) Dow Jones Newswires

January 22, 2024 01:44 ET (06:44 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Novartis 차트를 더 보려면 여기를 클릭.
Novartis (NYSE:NVS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Novartis 차트를 더 보려면 여기를 클릭.